

# Nosocomial Outbreak-Derived *Serratia marcescens*: In Vitro Susceptibility to Antimicrobial Agents in Comparison with Carbapenem-Resistant Strains

Ikue TANEIKE, Saori NAKAGAWA, Akira IWAYA and Tatsuo YAMAMOTO

Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Received July 11 2002; accepted October 1 2002

**Summary.** *Serratia marcescens* strains derived from an outbreak of nosocomial septicaemia in Tokyo were tested for their in vitro susceptibilities to 43 antimicrobial agents, in comparison with carbapenem-resistant strains isolated from other hospitals in Tokyo. The outbreak-derived strains were highly susceptible to 4th-generation cepheims, oxacephems, monobactams, carbapenems, newer fluoroquinolones and trimethoprim, but highly resistant to penicillins, 1st- and 2nd-generation cepheims and macrolides, and moderately resistant to many of 3rd-generation cepheims, penems, aminoglycosides and sulfamethoxazole. These data markedly contrasted to those of carbapenem-resistant strains isolated in Tokyo that exhibited resistance (or lower susceptibility) to most of the antimicrobial agents except for monobactams and trimethoprim. Effects of  $\beta$ -lactamase inhibitors, and glucose-6-phosphate on the minimum inhibitory concentrations (MICs) of fosfomycin were also examined. The data indicate that the nosocomial outbreak of *S. marcescens* was not primarily due to bacterial multiple drug resistance, and highlights the importance of control with susceptible antimicrobial agents in the early stages of a blood stream infection.

**Key words**—*Serratia marcescens*, a nosocomial outbreak, in vitro susceptibility.

## INTRODUCTION

*Serratia marcescens* is recognized as an important bacterial pathogen in hospital-acquired infection<sup>1,2</sup>.

Carbapenems are often recommended for the treatment of blood stream infections due to *S. marcescens*, however, multiple drug-resistant *S. marcescens*, which exhibits resistance even to carbapenems, has also been reported<sup>3–7</sup>.

Recently, three large nosocomial outbreaks of *S. marcescens* infection (septicaemia) with unclarified routes of infection have occurred in Japan, although one factor common to all the patients was drip infusion. The first incidence occurred in Tokyo in July 1999, with 10 patients and five fatalities<sup>8</sup>. During May–July 2000, the second incidence occurred in Osaka with 15 patients infected and eight fatalities<sup>9</sup>, and the third incidence occurred in Tokyo in January 2002 with 12 patients infected and seven fatalities.

In this study, we investigated the in vitro susceptibility of the outbreak-derived *S. marcescens* strains (isolated in Tokyo in July 1999) to 43 antimicrobial agents, and the minimum inhibitory concentration (MIC) data were compared with those of the carbapenem-resistant *S. marcescens* strains isolated from other hospitals in Tokyo.

## MATERIALS AND METHODS


### Bacterial strains

*S. marcescens* strains (ten strains), derived from a nosocomial outbreak in Tokyo in 1999<sup>8</sup> (Fig. 1), were kindly provided by Miyoko Endoh (Tokyo Metropolitan Research Laboratory of Public Health, Tokyo).

**Correspondence:** Tatsuo Yamamoto, Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental

Sciences, 1-757, Asahimachidori, Niigata, Japan.

**Abbreviations**—CFU, colony forming unit, LB broth, Luria-Bertani broth, MIC, minimum inhibitory concentration.



**Fig. 1.** Nosocomial outbreaks of *S. marcescens* blood-stream infection in Japan in the last three years

They are indistinguishable from each other by pulsed-field gel electrophoresis<sup>8</sup>). Carbapenem-resistant *S. marcescens* strains (strains TO1, TO2 and TO3), isolated in Tokyo, were kindly provided by Toyoko Oguri (Juntendo University, Tokyo). They were stored at  $-80^{\circ}\text{C}$  in 3% skim milk (Difco Laboratories, Detroit, Mich., USA) supplemented with 5% glucose (Difco). They were negative for the prodigiosin (a red pigment) production.

#### Media and bacterial growth

For bacterial growth, we used LB broth (Difco Laboratories, Detroit, Mich., USA) as the liquid media; this was inoculated and incubated at  $37^{\circ}\text{C}$  for 12-18 h with agitation. Nutrient agar (Eiken Chemical, Tokyo) and Mueller-Hinton agar (Difco) were used as solid media.

#### Antimicrobial agents

Each of antimicrobial agents was a gift from their

manufacturers. They included: ampicillin (Meiji Seika, Tokyo), amoxicillin (Fujisawa Pharmaceutical Co., Tokyo) and piperacillin (Toyama Chemical Co., Tokyo) as penicillins; cefazolin (Fujisawa Pharmaceutical Co.), cefaclor (Shionogi & Co., Osaka), cefotiam (Takeda Chemical Industries, Osaka), cefixime (Fujisawa Pharmaceutical Co.), ceftazidime (Glaxosmithkline K.K., Tokyo), ceftriaxone, (Nippon Roche, Tokyo), cefotaxime (Sigma, St. Louis, MO, USA), cefoperazone (Toyama Chemical Co.), cefepime (Bristol-Myers Squibb K.K., Tokyo), ceftazopran (Takeda Chemical Industries) and cefpirome (Shionogi & Co.) as cefems; latamoxef (Shionogi & Co.) and flomoxef (Shionogi & Co.) as oxacephems; aztreonam (Eisai Co., Tokyo) and carumonam (Takeda Chemical Industries) as monobactams; imipenem (Banyu Pharmaceutical Co., Tokyo), panipenem (Sankyo Co., Tokyo) and meropenem (Sumitomo Pharmaceuticals Co., Osaka) as carbapenems; faropenem (Suntory pharmaceutical division, Osaka) as penems; amikacin (Meiji Seika), gentamicin (Schering-Plough K.K., Osaka),

kanamycin (Meiji Seika), streptomycin (Meiji Seika) and isepamicin (Schering-Plough K.K., U.S.A.) as aminoglycosides; tetracycline (Wyeth Lederle Japan, Tokyo), doxycycline (Pfizer Pharmaceuticals Inc., Tokyo) and minocycline (Wyeth Lederle Japan) as tetracyclines; erythromycin (Shionogi & Co.), roxithromycin (Aventis Pharma, Tokyo), clarithromycin (Taisho Pharmaceutical Co., Tokyo) and azithromycin (Pfizer Pharmaceuticals Inc.) as macrolides; nalidixic acid (Daiichi Pharmaceutical Co., Tokyo), norfloxacin (Daiichi Pharmaceutical Co., Tokyo), ciprofloxacin (Bayer Yakuhin, Osaka), ofloxacin (Daiichi Pharmaceutical Co.) and levofloxacin (Daiichi Pharmaceutical Co.) as quinolones; chloramphenicol (Sankyo Co.); trimethoprim (Shionogi & Co.); sulfamethoxazole (Shionogi & Co.); and fosfomycin (Meiji Seika).

### Reagents

Each of  $\beta$ -lactamase inhibitors, clavulanic acid (GlaxoSmithKline K.K.), sulbactam (Pfizer Pharmaceuticals Inc.) and tazobactam (Toyama Chemical Co.) was a gift from their manufacturers. Clavulanic acid was added to amoxicillin at the ratio of 1:2 (as in the combination drug), sulbactam was added to ampicillin and cefoperazone at the ratio of 1:2 and 1:1, respectively (as in the combination drug), and tazobactam was added to piperacillin at a concentration of 4  $\mu\text{g/ml}$ , as described previously<sup>10</sup>. D-Glucose-6-phosphate was purchased from Wako Pure Chemical Industries, Osaka.

### Susceptibility testing

Susceptibility testing of the bacterial strains was performed using the agar dilution method with Mueller-Hinton agar according to standard procedures<sup>10,11</sup>. The final concentrations of the antimicrobial agents ranged from 0.002 to 128  $\mu\text{g/ml}$ . The test bacteria were grown for 18 h at 37°C with agitation in LB broth, and diluted to approximately  $10^6$  colony-forming unit (CFU)/ml. Aliquots of the bacterial suspension (approximately  $10^4$  CFU of bacteria per spot) were inoculated on the surface of agar plates containing the antimicrobial agents. Incubation was for 18 h at 35°C. The MICs were determined as described previously<sup>10,11</sup>. *E. coli* NIHJ JC-2 was used as a reference strain for quality control<sup>11</sup>. When the susceptibility to sulfamethoxazole or trimethoprim was tested, Mueller-Hinton agar supplemented with and without 7.5% (vol/vol) defibrinated horse blood (frozen and thawed) was used<sup>12</sup>. When the susceptibility to fosfomycin was tested, Mueller-

Hinton agar supplemented with glucose-6-phosphate (10 or 50  $\mu\text{g/ml}$ ) was used, in addition to Mueller-Hinton agar alone<sup>13</sup>.

## RESULTS

### In vitro susceptibility of the nosocomial outbreak-derived *S. marcescens* strains

The MICs of the antimicrobial agents against the *S. marcescens* strains are summarized in Table 1. The

**Table 1.** MICs of antimicrobial agents for the nosocomial outbreak-derived *S. marcescens* strains and the carbapenem-resistant *S. marcescens* strains

Antimicrobial agent	MIC ( $\mu\text{g/ml}$ ) <sup>a)</sup>	
	Outbreak-derived strains (n=10)	Carbapenem-resistant strains (n=3)
<b>Penicillins</b>		
Ampicillin	$\geq 256$	$\geq 256$
Ampicillin+Sulbactam <sup>b)</sup>	$\geq 256$	$\geq 256$
Amoxicillin	$\geq 256$	$\geq 256$
Amoxicillin+Clavulanic acid <sup>c)</sup>	128	128– $\geq 256$
Piperacillin	16	32–128
Piperacillin+Tazobactam <sup>d)</sup>	8	8–16
<b>Cephems</b>		
(the 1st-generation)		
Cefazolin	$\geq 256$	$\geq 256$
Cefaclor	$\geq 256$	$\geq 256$
(the 2nd-generation)		
Cefotiam	$\geq 256$	$\geq 256$
(the 3rd-generation)		
Cefixime	8	$\geq 256$
Ceftazidime	0.5	$\geq 256$
Ceftriaxone	2	$\geq 256$
Cefotaxime	4	$\geq 256$
Cefoperazone	16	$\geq 256$
Cefoperazone+Sulbactam <sup>e)</sup>	8	$\geq 256$
(the 4th-generation)		
Cefepime	0.13	128– $\geq 256$
Cefozopran	0.13	128– $\geq 256$
Cefpirome	0.06	64–128
<b>Oxacephems</b>		
Latamoxef	2	$\geq 256$
Flomoxef	1	$\geq 256$
<b>Monobactams</b>		
Aztreonam	1	0.25–1
Carumonam	0.5	0.13–1

Table 1. (continued)

Carbapenems		
Imipenem	0.25	128-≥ 256
Panipenem	0.25	≥ 256
Meropenem	0.03	64-128
Penems		
Faropenem	16	≥ 256
Aminoglycosides		
Amikacin	8	8-128
Gentamicin	1	8-64
Kanamycin	32	≥ 256
Streptomycin	2	4-128
Isepamicin	2	4-64
Tetracyclines		
Tetracycline	8	128-≥ 256
Doxycycline	4	16-64
Minocycline	2	4-32
Macrolides		
Erythromycin	≥ 256	64-≥ 256
Roxithromycin	≥ 256	≥ 256
Clarithromycin	≥ 256	128-≥ 256
Azithromycin	64	32-128
Quinolones		
(Older)		
Nalidixic acid	2	2-≥ 256
(Newer)		
Norfloxacin	0.06	1-32
Ciprofloxacin	0.03	0.25-8
Ofloxacin	0.13	1-16
Levofloxacin	0.06	0.5-8
Chloramphenicol	16	16
Others		
Trimethoprim	0.5	0.25-4
Sulfamethoxazole	32	≥ 256
Fosfomycin	≥ 256	≥ 256
Fosfomycin + G 6 P <sup>d)</sup>	32	64-≥ 256
Fosfomycin + G 6 P <sup>g)</sup>	32	32-≥ 256

a) Range; b) Ampicillin: Sulbactam=2 : 1<sup>10</sup>; c) Amoxicillin: Clavulanic acid=2 : 1<sup>10</sup>; d) Tazobactam at a fixed concentration of 4 µg/ml<sup>10</sup>; e) Cefoperazone: Sulbactam=1 : 1<sup>10</sup>; f) In the presence of 10 µg/ml of glucose-6-phosphate; g) In the presence of 50 µg/ml of glucose-6-phosphate.

MIC was essentially the same in each of the 10 nosocomial outbreak-derived strains. With respect to the penicillins, the strains were highly resistant to ampicillin and amoxicillin, and moderately resistant to piperacillin. Among the penicillins, the combination of piperacillin and tazobactam ( $\beta$ -lactamase inhibitor) showed the greatest activity, although the addition of tazobactam to piperacillin resulted in a decrease in the MIC values to some extent.

In the case of cepheims, the strains were highly resistant to the 1st- and the 2nd-generation cepheims and moderately resistant (or poorly susceptible) to many of the 3rd-generation cepheims. Among the 3rd-generation cepheims, ceftazidime showed the highest activity. The addition of sulbactam to cefoperazon resulted in no drastic improvement in susceptibility. The strains were susceptible to the 4th-generation cepheims.

With respect to other  $\beta$ -lactam antimicrobial agents, the strains were moderately resistant to faropenem (penems), but were susceptible to the oxacephems, monobactams, and carbapenems.

The strains were resistant to some of aminoglycosides (e.g. kanamycin), macrolides, chloramphenicol, sulfamethoxazole and fosfomycin. They were very susceptible to newer fluoroquinolones and trimethoprim. The addition of glucose-6-phosphate to fosfomycin lowered the MIC values when compared with fosfomycin alone.

Among the antimicrobial agents tested, meropenem and ciprofloxacin showed the highest activity (MIC ≤ 0.03 µg/ml). These were followed by cefpirime, norfloxacin, and levofloxacin (MIC ≤ 0.06 µg/ml).

#### In vitro susceptibility of carbapenem-resistant *S. marcescens* strains

The carbapenem-resistant *S. marcescens* strains were resistant to most of the antimicrobial agents (Table 1). They were susceptible only to the monobactams among  $\beta$ -lactam antimicrobial agents (MIC ≤ 1 µg/ml). The strains were also relatively susceptible to trimethoprim (MIC ≤ 4 µg/ml). The MIC of piperacillin decreased more rapidly with the addition of tazobactam, compared with the case of the outbreak-derived strains.

#### DISCUSSION

There have been three large-scale hospital outbreaks of *S. marcescens* infection in Japan<sup>8,9</sup>. In the infected individuals who developed symptoms, the onset was a

spike-pattern fever accompanied by shaking, and *S. marcescens* was isolated during the fever period. In the past two hospital outbreaks (in 1999 and 2000), an analysis of isolates by pulsed-field gel electrophoresis showed an identical pattern<sup>8,9</sup>. The molecular DNA data of the *S. marcescens* strains in the third outbreak in 2002 have not been reported.

The mortality in the *S. marcescens* blood stream infection was high: 50% (5 of 10 patients) in the outbreak in Tokyo in 1999<sup>8</sup>, 53% (8 of 15 patients) in the outbreak in Osaka in 2000<sup>9</sup>, and 58% (7 of 12 patients) in the outbreak in Tokyo in 2002. In the outbreak in Tokyo in 1999, those patients with severe infection developed respiratory failure, disseminated intravascular coagulation (DIC), or shock, which progressed to multiple organ failure (MOF)<sup>8</sup>.

With respect to the *S. marcescens* strains derived from the nosocomial outbreaks in Tokyo in 1999<sup>8</sup> and in Osaka in 2000<sup>9</sup>, the in vitro susceptibility data were obtained with some antimicrobial agents by the disc-diffusion method. However, no precise MIC values for each antimicrobial agent obtained by the agar dilution method have been reported. In this study, we investigated the in vitro susceptibility of the outbreak-derived *S. marcescens* strains (Tokyo strains in 1999) to 43 antimicrobial agents.

For the treatment of *S. marcescens* infection, carbapenem is often recommended as for *Pseudomonas aeruginosa* infection. The nosocomial infection isolates (Tokyo strains in 1999) investigated in this study were highly susceptible to the carbapenems. The isolates were also susceptible to the 4th-generation cepheims, monobactams, newer fluoroquinolones and trimethoprim, although they were resistant to some other antimicrobial agents such as penicillins and the 1st- and the 2nd-generation cepheims. The addition of  $\beta$ -lactamase inhibitors to ampicillin, amoxicillin, piperacillin or cefoperazone did not drastically decrease the high MIC values.

Based on the MIC patterns for  $\beta$ -lactam antimicrobial agents, it was speculated that the outbreak strains possess class C  $\beta$ -lactamase (cephalosporinase)<sup>14,15</sup>, which is characterized by a high level of resistance to ampicillin and the 1st- and the 2nd-generation cepheims and a low level of resistance to piperacillin (this piperacillin resistance is only slightly lowered by the presence of tazobactam).

The fosfomycin activity estimated in vitro is influenced by the assay conditions<sup>13</sup>. For instance, the MIC of fosfomycin is lowered by the addition of sugar ester (such as glucose-6-phosphate) in the medium or by incubation under anaerobic conditions. In this study, the addition of glucose-6-phosphate to fosfomycin lowered the MIC values. Fosfomycin is

transported into the bacterial cells via at least two transport systems, the sn-glycerol 3-phosphate transport (GlpT) system and the hexose phosphate transport (UhpT) system<sup>13</sup>. The latter is induced with glucose-6-phosphate. There is a possibility that fosfomycin is transported mainly by the UhpT system in the *S. marcescens* strains, as in e.g. *Escherichia coli* and *Staphylococcus aureus*<sup>13</sup>, and therefore, the MICs of fosfomycin was lowered by the presence of glucose-6-phosphate. Fosfomycin reaches a serum concentration of 166  $\mu$ g/ml following an intravenous injection at 50 mg/kg<sup>16</sup>. Further studies are necessary to evaluate the protective effect of fosfomycin against the *S. marcescens* infection in vivo.

In the outbreak in Tokyo in 1999, ceftazidime (4th-generation cephem) or isepamicin (aminoglycoside) were administered to the three patients who exhibited the most rapid course, but their symptoms did not improve, and the patients died<sup>8</sup>. It is necessary to carry out a further epidemiological survey on the *S. marcescens* infection. In addition, it may be important to administer effective doses of antimicrobial agents such as carbapenems (and newer fluoroquinolones), which have been recommended in empiric therapy, during the early phase after infection.

Although its frequency is low, there have been cases of a multiple drug-resistant *S. marcescens*, which exhibits resistance even to carbapenems<sup>3-7</sup>. In this study, we also analyzed the carbapenem-resistant *S. marcescens* strains isolated in other hospitals in Tokyo. These isolates were resistant to most of the antimicrobial agents examined, and were susceptible to only limited antimicrobial agents such as monobactams and trimethoprim.

Integron, which is a resistance gene-joining system, is attracting attention for its genetic resistance mechanism<sup>17,18</sup>. Class III integron has been isolated from *S. marcescens*, and its genetic structure contains a gene encoding for resistance to carbapenems and a gene encoding for resistance to amikacin and gentamycin<sup>3</sup>. Class I integron encoding for resistance to carbapenems has also been reported<sup>7</sup>. Various resistance-genes are involved in *S. marcescens* resistance, and exhibit complicated resistance-phenotypes. For example, the carbapenem-resistant isolates analyzed in this study were susceptible to monobactams, while those in many other reports were resistant to monobactams<sup>4-7</sup>.

The precise resistance-mechanism(s) of the present carbapenem-resistant *S. marcescens* strains is under investigation. However, based on the MIC patterns for  $\beta$ -lactam antimicrobial agents, it has been speculated that the carbapenem-resistant strains possess at least three  $\beta$ -lactamases: 1) class B  $\beta$ -

lactamase (metallo- $\beta$ -lactamase)<sup>14,19</sup> which is responsible for resistance to carbapenems, cepheims and oxacepheims; 2) class A  $\beta$ -lactamase (penicillinase)<sup>14,19</sup> which is responsible for a high level of resistance to piperacillin (this piperacillin resistance is markedly lowered by the presence of tazobactam); and 3) class C  $\beta$ -lactamase<sup>14,15</sup>, similar to the outbreak-derived strains. Fortunately, no large outbreak of hospital infection by the multiple drug-resistant *S. marcescens* has ever been reported in Japan.

In the outbreak in Tokyo in 1999, the use of 50% isopropanol -- which is easily degraded -- to disinfect the drip infusion port was suggested to be the cause of the hospital infection<sup>9</sup>.

It has been thought that the *S. marcescens* infection in the three nosocomial outbreaks in 1999, 2000 and 2002, which may have been transmitted via a catheter, was an opportunistic infection and that the deaths were due to endotoxic shock. However, bacteriologically speaking, there are many questions: 1) Why was *S. marcescens* a causative agent of the hospital infection in the three outbreaks? Why was not it, (e.g. *P. aeruginosa* or *Enterobacter* spp.) which was considered to have a similar contamination route in hospitals? Does *S. marcescens* possess a specific defense system against humoral immunity? 2) Was the main cause of the deaths actually endotoxic shock? In the outbreak in Tokyo in 1999, serum endotoxin was measured in five of 10 patients<sup>9</sup>. In one death, the serum endotoxin level was higher than the cutoff value -- 10 pg/ml -- and consistent with the clinical symptoms, but the level was lower than the cutoff value in the other four patients.

The mortality rate was extremely high, with respective tolls of two patients (20%), three patients (20%), and three patients (25%) dying within two days after the spike-pattern fever in the outbreaks in Tokyo in 1999<sup>9</sup>, Osaka in 2000<sup>9</sup>, and Tokyo in 2002. It is possible that the deaths may have been caused by systemic inflammatory response syndrome (SIRS)<sup>20</sup> followed by bacteremia and by endogenous anandamide<sup>21-23</sup>. It is also possible that *S. marcescens* produces an unknown virulent factor (lethal factor) or has a virulent mechanism. For example, *S. marcescens* produces a metalloprotease highly homologous to the elastase produced by *P. aeruginosa*. A detailed investigation of the pathogenicity of *S. marcescens* in the circulation (blood stream infection mechanism) is necessary.

In conclusion, the *S. marcescens* nosocomial outbreaks in Tokyo in 1999 were not primarily due to bacterial multiple drug resistance. Although there are points to be clarified in the mechanism of *S.*

*marcescens* blood stream infection, for treatment, it is important to administer effective doses of antimicrobial agents -- e.g. the carbapenems (and newer fluoroquinolones) which have been recommended in empiric therapy -- during the early phase after infection, and for medical staff to make greater efforts to prevent *S. marcescens* contamination of (e.g.) infusion systems.

## REFERENCES

- 1) Hejazi A, Aucken HM, Falkiner FR: Epidemiology and susceptibility of *Serratia marcescens* in a large general hospital over an 8-year period. *J Hosp Infect* **45**: 42-46, 2000.
- 2) Hejazi A, Falkiner FR: *Serratia marcescens*. *J Med Microbiol* **46**: 903-912, 1997.
- 3) Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, Shimokata K, Kato N, Ohta M: PCR detection of metallo- $\beta$ -lactamase gene (*bla<sub>IMP</sub>*) in gram-negative rods resistant to broad-spectrum  $\beta$ -lactams. *J Clin Microbiol* **34**: 2909-2913, 1996.
- 4) Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC Jr, Quinn JP, Hindler J, Medeiros AA, Bush K: SME-type carbapenem-hydrolyzing class A  $\beta$ -lactamases from geographically diverse *Serratia marcescens* strains. *Antimicrob Agents Chemother* **44**: 3035-3039, 2000.
- 5) Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN: Carbapenem-resistant *Serratia marcescens* isolates producing Bush group 2f  $\beta$ -lactamase (SME-1) in the United States: results from the MYSTIC programme. *Diagn Microbiol Infect Dis* **39**: 125-127, 2001.
- 6) Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M: Plasmid-encoded metallo- $\beta$ -lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. *Antimicrob Agents Chemother* **45**: 1343-1348, 2001.
- 7) Yum JH, Yong D, Lee K, Kim HS, Chong Y: A new integron carrying VIM-2 metallo- $\beta$ -lactamase gene cassette in a *Serratia marcescens* isolate. *Diagn Microbiol Infect Dis* **42**: 217-219, 2002.
- 8) Report of the study group for disease of unknown cause. Tokyo: Bureau of Public Health Tokyo Metropolitan Government 2000. (in Japanese)
- 9) The report of nosocomial *Serratia marcescens* outbreak in Sakai city. Sakai city government public health and welfare bureau 2000. (in Japanese)
- 10) National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing, 12th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pa: PM100-S12, 2002.
- 11) Japan Society of Chemotherapy: Committee report. *Chemotherapy* (Tokyo) **29**: 76-79, 1981.
- 12) Japan Society of Chemotherapy: Committee report:

- methods of sensitivity testing for sulfamethoxazole-trimethoprim combination product. *Chemotherapy* (Tokyo) **21**: 67-76, 1973.
- 13) Dette GA, Knothe H, Schonenbach B, Plage G: Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. *J Antimicrob Chemother* **11**: 517-524, 1983.
  - 14) Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for  $\beta$ -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* **39**: 1211-1233, 1995.
  - 15) Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type  $\beta$ -lactamases. *Antimicrob Agents Chemother* **46**: 1-11, 2002.
  - 16) Koh B, Izawa Y, Sugiyama H, Aoyama H, Komiya I: Transfer of fosfomycin into human burn blister fluid and its pharmacokinetic analysis. *Jpn J Antibiot* **39**: 2863-2868, 1986. (in Japanese)
  - 17) Fluit AC, Schmitz FJ: Class 1 integrons, gene cassettes, mobility, and epidemiology. *Eur J Clin Microbiol Infect Dis* **18**: 761-770, 1999.
  - 18) White PA, McIver CJ, Rawlinson WD: Integrons and gene cassettes in the *Enterobacteriaceae*. *Antimicrob Agents Chemother* **45**: 2658-2661, 2001.
  - 19) Nordmann P, Poirel L: Emerging carbapenemases in Gram-negative aerobes. *Clin Microbiol Infect* **8**: 321-331, 2002.
  - 20) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* **20**: 864-874, 1992.
  - 21) Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G: Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. *Nature* **390**: 518-521, 1997.
  - 22) Varga K, Wagner JA, Bridgen DT, Kunos G: Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. *FASEB J* **12**: 1035-1044, 1998.
  - 23) Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I: Polymyxin B binds to anandamide and inhibits its cytotoxic effect. *FEBS Lett* **470**: 151-155, 2000.